Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
Authors:ID Gavrič, Ana Uršula (Author)
ID Ocvirk, Janja (Author)
ID Jaki Mekjavić, Polona (Author)
Files:.pdf PDF - Presentation file, download (769,16 KB)
MD5: 50D507D17D879067B8D9E593923D3D9B
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to follow this treatment. The study was aimed to investigate ocular toxicity in patients with metastatic melanoma treated with cobimetinib in combina-tion with vemurafenib.Patients and methods. In the prospective, observational study, patients with BRAF-mutated metastatic melanoma treated with cobimetinib in combination with vemurafenib at the Institute of Oncology Ljubljana were asked to par-ticipate. Ophthalmic examination was performed including measurement of visual acuity and intraocular pressure, slit lamp examination, funduscopy (CF), infrared-reflectance (IR) imaging and optical coherence tomography (OCT). Results. Five out of 7 patients noticed changes in vision few days after starting the therapy with cobimetinib. In all patients, small circular lesions, described as MEKAR lesions, were documented in outer retinal layers demonstrated with OCT, IR, and CF. Changes were in the center and/or scattered over the retina almost symmetrical in both eyes in 6 patients, and asymmetrical in one patient, the latter presented also with unilateral anterior uveitis and cystoid macular edema.Conclusions. Multiple bilateral foveal and extrafoveal small retinal lesions in the outer retinal layers develop in patients treated with MEK inhibitor in combination with BRAF inhibitor. Ophthalmologists and oncologists need to be aware of this common, yet relatively benign and often transient ocular side effect to avoid needless intervention, including the discontinuance of a potentially life-prolonging therapy.
Keywords:metastatic malignant melanoma, eye, MEK inhibitor, MEKAR
Publication status:Published
Publication version:Version of Record
Publication date:01.06.2018
Publisher:Association of Radiology and Oncology
Year of publishing:2018
Number of pages:str. 213-219, VII
Numbering:Vol. 52, no. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-19076 New window
UDC:616-006
ISSN on article:1318-2099
DOI:10.2478/raon-2018-0002 New window
COBISS.SI-ID:2876795 New window
Copyright:by Authors
Publication date in DiRROS:10.06.2024
Views:53
Downloads:18
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:metastatski maligni melanom, oči, zaviralec MEK, inhibitor MEK


Back